文献速递乳腺癌

高危乳腺癌伴≥4枚腋窝淋巴结转移患者的高剂量化疗联合造血干细胞移植:3期随机临床试验20年随访

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究对885例56岁以下、≥4枚腋窝淋巴结阳性的乳腺癌患者进行20年随访,比较辅助高剂量化疗联合造血干细胞移植(HDCT)与常规剂量化疗(CDCT)。HDCT在总体人群中未显著改善20年总生存(45.3% vs 41.5%,HR 0.89,95%CI 0.75-1.06),但在≥10枚淋巴结阳性亚组绝对改善14.6%(HR 0.72,95%CI 0.54-0.95),且未增加第二恶性肿瘤或主要心血管事件累积风险。

要点

  • HDCT在总体人群未显著改善20年OS,HR 0.89(95%CI 0.75-1.06)。
  • ≥10枚淋巴结阳性者HDCT绝对OS改善14.6%(HR 0.72,95%CI 0.54-0.95)。
  • HDCT未增加20年第二肿瘤或主要心血管事件风险,但高血压等更常见。

核心结论

  • 在未选择的III期乳腺癌患者中,辅助HDCT未带来长期生存获益。
  • 在≥10枚腋窝淋巴结阳性的极高危患者中,HDCT可改善20年总生存。
  • HDCT未影响20年第二恶性肿瘤或主要心血管事件的累积风险。

研究设计与样本

  • 随机3期多中心临床试验的二次分析,纳入885例56岁以下、≥4枚腋窝淋巴结阳性的乳腺癌女性。
  • 1993年8月1日至1999年7月31日入组,2016年6月1日至2017年12月31日补充随访,按意向性治疗分析。
  • 参与者1:1随机接受5周期CDCT或HDCT(前4周期同CDCT,第5周期替换为环磷酰胺6000 mg/m2、塞替派480 mg/m2、卡铂1600 mg/m2后行造血干细胞移植)。

主要发现

  • 中位随访20.4年(IQR 19.2-22.0),HDCT组20年总生存45.3%,CDCT组41.5%(HR 0.89,95%CI 0.75-1.06)。
  • ≥10枚腋窝淋巴结阳性患者中,HDCT组20年OS绝对改善14.6%(HR 0.72,95%CI 0.54-0.95)。
  • 三阴性乳腺癌患者中,HDCT组20年OS绝对改善15.4%(HR 0.67,95%CI 0.42-1.05)。

临床怎么用

  • 对≥4枚淋巴结阳性但未达极高危的III期乳腺癌,不推荐常规辅助HDCT。
  • 对≥10枚腋窝淋巴结阳性的极高危患者,HDCT联合造血干细胞移植可作为个体化治疗选择。
  • HDCT决策需权衡长期生存获益与高血压、高胆固醇血症及心律失常风险增加。

局限性

  • 为二次分析,亚组结果(如≥10枚淋巴结、三阴性)需谨慎解读。
  • 随访数据来自医疗记录和登记数据库,可能存在信息偏倚。
  • 研究入组于1993-1999年,治疗方案与当前临床实践存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Trials of adjuvant high-dose chemotherapy (HDCT) have failed to show a survival benefit in unselected patients with breast cancer, but long-term follow-up is lacking. OBJECTIVE: To determine 20-year efficacy and safety outcomes of a large trial of adjuvant HDCT vs conventional-dose chemotherapy (CDCT) for patients with stage III breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis used data from a randomized phase 3 multicenter clinical trial of 885 women younger than 56 years with breast cancer and 4 or more involved axillary lymph nodes conducted from August 1, 1993, to July 31, 1999. Additional follow-up data were collected between June 1, 2016, and December 31, 2017, from medical records, general practitioners, the Dutch national statistical office, and nationwide cancer registries. Analysis was performed on an intention-to-treat basis. Statistical analysis was performed from February 1, 2018, to October 14, 2019. INTERVENTIONS: Participants were randomized 1:1 to receive 5 cycles of CDCT consisting of fluorouracil, 500 mg/m2, epirubicin, 90 mg/m2, and cyclophosphamide, 500 mg/m2, or HDCT in which the first 4 cycles were identical to CDCT and the fifth cycle was replaced by cyclophosphamide, 6000 mg/m2, thiotepa, 480 mg/m2, and carboplatin, 1600 mg/m2, followed by hematopoietic stem cell transplant. MAIN OUTCOMES AND MEASURES: Main end points were overall survival and safety and cumulative incidence risk of a second malignant neoplasm or cardiovascular events. RESULTS: Of the 885 women in the study (mean [SD] age, 44.5 [6.6] years), 442 were randomized to receive HDCT, and 443 were randomized to receive CDCT. With 20.4 years median follow-up (interquartile range, 19.2-22.0 years), the 20-year overall survival was 45.3% with HDCT and 41.5% with CDCT (hazard ratio, 0.89; 95% CI, 0.75-1.06). The absolute improvement in 20-year overall survival was 14.6% (hazard ratio, 0.72; 95% CI, 0.54-0.95) for patients with 10 or more invoved axillary lymph nodes and 15.4% (hazard ratio, 0.67; 95% CI, 0.42-1.05) for patients with triple-negative breast cancer. The cumulative incidence risk of a second malignant neoplasm at 20 years or major cardiovascular events was similar in both treatment groups (20-year cumulative incidence risk for second malignant neoplasm was 12.1% in the HDCT group vs 16.2% in the CDCT group, P = .10), although patients in the HDCT group more often had hypertension (21.7% vs 14.3%, P = .02), hypercholesterolemia (15.7% vs 10.6%, P = .04), and dysrhythmias (8.6% vs 4.6%, P = .005). CONCLUSIONS AND RELEVANCE: High-dose chemotherapy provided no long-term survival benefit in unselected patients with stage III breast cancer but did provide improved overall survival in very high-risk patients (ie, with ≥10 involved axillary lymph nodes). High-dose chemotherapy did not affect long-term risk of a second malignant neoplasm or major cardiovascular events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03087409.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Steenbruggen TG, Steggink LC, Seynaeve CM, et al. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 31999296. doi:10.1001/jamaoncol.2019.6276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。